2149-70-4 Usage
Description
N'-Nitro-L-arginine, also known as L-NNA or NG-nitro-L-arginine, is an organic compound and a potent competitive inhibitor of nitric oxide synthase (NOS). It is a derivative of the amino acid L-arginine, with a nitro group (-NO2) attached to the nitrogen atom at the ω (omega) position. N'-Nitro-L-arginine is a white to off-white powder and is widely used in scientific research to study the role of nitric oxide in various biological processes.
Uses
Used in Pharmaceutical Research:
N'-Nitro-L-arginine is used as a research chemical for the inhibition of nitric oxide synthase, which is essential in understanding the role of nitric oxide in various physiological and pathological conditions. By inhibiting NOS, researchers can investigate the effects of nitric oxide on blood vessels, immune response, and neurotransmission.
Used in Bacteriology:
N'-Nitro-L-arginine is used as a tool in the study of bacteria, particularly to determine effective treatments against certain bacterial infections. It can help researchers understand the role of nitric oxide in bacterial pathogenesis and develop targeted therapies.
Used in the Study of MRSA (Methicillin-Resistant Staphylococcus Aureus):
N'-Nitro-L-arginine is employed in the research of MRSA, a type of antibiotic-resistant bacteria. By inhibiting nitric oxide synthase, researchers can study the effects of nitric oxide on MRSA's virulence, resistance mechanisms, and potential treatment strategies.
Hazard
A reproductive hazard.
Biological Activity
NO synthase inhibitor.
Biochem/physiol Actions
Nω-Nitro-L-arginine/L-NNA helps to reduce the levels of cortical hyperemia and brain cGMP occurring due to hypercapnia.
Safety Profile
Experimental reproductiveeffects. When heated to decomposition it emits toxicvapors of NOx.
Check Digit Verification of cas no
The CAS Registry Mumber 2149-70-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,1,4 and 9 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 2149-70:
(6*2)+(5*1)+(4*4)+(3*9)+(2*7)+(1*0)=74
74 % 10 = 4
So 2149-70-4 is a valid CAS Registry Number.
InChI:InChI=1/C6H13N5O4/c7-6(8)9-3-1-2-4(5(12)13)10-11(14)15/h4,10H,1-3H2,(H,12,13)(H4,7,8,9)
2149-70-4Relevant articles and documents
Direct monitoring of biocatalytic deacetylation of amino acid substrates by1H NMR reveals fine details of substrate specificity
De Cesare, Silvia,McKenna, Catherine A.,Mulholland, Nicholas,Murray, Lorna,Bella, Juraj,Campopiano, Dominic J.
supporting information, p. 4904 - 4909 (2021/06/16)
Amino acids are key synthetic building blocks that can be prepared in an enantiopure form by biocatalytic methods. We show that thel-selective ornithine deacetylase ArgE catalyses hydrolysis of a wide-range ofN-acyl-amino acid substrates. This activity was revealed by1H NMR spectroscopy that monitored the appearance of the well resolved signal of the acetate product. Furthermore, the assay was used to probe the subtle structural selectivity of the biocatalyst using a substrate that could adopt different rotameric conformations.
Design, synthesis and primary activity assay of bi- or tri-peptide analogues with the scaffold l-arginine as amino-peptidase N/CD13 inhibitors
Mou, Jiajia,Fang, Hao,Liu, Yingzi,Shang, Luqing,Wang, Qiang,Zhang, Lei,Xu, Wenfang
scheme or table, p. 887 - 895 (2010/05/02)
A series of bi- or tri-peptide analogues with the scaffold l-arginine were designed, synthesized and evaluated for their inhibitory activities against amino-peptidase N (APN) and metalloproteinase-2 (MMP-2). The primary activity assay showed that all the compounds exhibited higher inhibitory activities against APN than MMP-2. Within this series, compounds C6 and C7 (IC50 = 4.2 and 4.3 μM) showed comparable APN inhibitory activities with the positive control bestatin (IC50 = 3.8 μM).
A new method of reducing nitroarginine-peptide into arginine-peptide, with reference to the synthesis of poly-L-arginine hydrochloride.
Hayakawa,Fujiwara,Noguchi
, p. 1205 - 1208 (2007/10/05)
-